'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023

Kyle LaHucik

Associate Editor

Enveda Biosciences will enter the clinic next year with at least one of its three main programs thanks to a $68 million boost in financing — about $55 million via equity and the remainder debt.

Founded by an early employee at AI startup Recursion Pharmaceuticals, Enveda has adjusted its priorities since disclosing a $51 million Series A in June 2021. At the time, CEO Viswa Colluru told Endpoints News the three core areas were Wilson disease, NASH and Parkinson’s.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

Full TIGIT data from Gilead, Arcus show lower PFS rates than December readout: #ASCO23

Bristol Myers' Opdivo keeps cancer at bay in more lymphoma patients than Seagen's Adcetris in PhIII: #ASCO23

Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23

AstraZeneca trial shows modest benefit in ovarian cancer, but doctors say it's hard to apply findings: #ASCO23

Novo Nordisk unveils $165M buyout bid for a drug delivery partner on smart insulin pens

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

'As the mar­ket has turned': Enve­da se­cures $68M to move re­vised pipeline in­to the clin­ic in 2023

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023

Full TIGIT data from Gilead, Arcus show lower PFS rates than December readout: #ASCO23

Bristol Myers' Opdivo keeps cancer at bay in more lymphoma patients than Seagen's Adcetris in PhIII: #ASCO23

Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23

AstraZeneca trial shows modest benefit in ovarian cancer, but doctors say it's hard to apply findings: #ASCO23

Novo Nordisk unveils $165M buyout bid for a drug delivery partner on smart insulin pens

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape